DOCSLIB.ORG

Long-Acting Injectable Antipsychotics During COVID-19 How to Determine If Your Patient Should Continue an LAI, and How to Do So Safely

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Long-Acting Injectable Antipsychotics During COVID-19 How to Determine If Your Patient Should Continue an LAI, and How to Do So Safely Long-acting injectable antipsychotics during COVID-19 How to determine if your patient should continue an LAI, and how to do so safely Kristina Schnitzer, MD ong-acting injectable antipsychotics (LAIs) are an essential tool Fellow, Public and Community Psychiatry Massachusetts General Hospital in the treatment of patients with psychotic disorders, allowing Boston, Massachusetts for periods of stable drug plasma concentration and confirmed L 1 Sarah MacLaurin, PMHNP-BC adherence. The current coronavirus disease 2019 (COVID-19) pan- Freedom Trail Clinic of North Suffolk Mental demic presents unique challenges for administering LAIs and requires Health Association a thoughtful and prospective approach in order to ensure continuity of Massachusetts General Hospital Boston, Massachusetts psychiatric care while minimizing the risk of infection with COVID-19. Oliver Freudenreich, MD, FACLP Ideally, patients should be seen in person as infrequently as clinically Co-Director, MGH Schizophrenia Clinical and prudent during this public health emergency; however, LAI administra- Research Program tion necessitates direct physical contact between patient and clinician. Associate Professor of Psychiatry Harvard Medical School Patients with serious mental illness (SMI), who comprise the majority Boston, Massachusetts of individuals who receive LAIs, are at heightened risk for cardiovascu- Disclosures lar and pulmonary comorbidities. These factors are the primary reason Dr. Freudenreich has received grant or research support the life expectancy of a patient with SMI is nearly 30 years shorter than from Alkermes, Avanir, Janssen, Otsuka, and Saladax, 2-5 and has served as a consultant to Alkermes, Janssen, that of the general population. The risk of health care workers becom- Neurocrine, Novartis, and Roche. Drs. Schnitzer and ing infected or inadvertently spreading COVID-19 is heightened when MacLaurin report no financial relationships with any companies whose products are mentioned in this article, working with patients in group living environments (ie, a shelter or or with manufacturers of competing products. group home), who have both increased exposure and increased risk of doi: 10.12788/cp.0087 further transmission.6 Additional patient populations, including older adults, immunocompromised individuals, and those with preexisting conditions, are at heightened risk for serious complications if they were to contract COVID-19.7,8 Thus, the questions of whether LAIs should be administered, and how to do so safely (both during the ongoing, acute phase of the pan- demic as well as during the subsequent recovery period until the pan- demic abates) need to be carefully considered. In this article, we provide concrete advice for clinicians and clinics on these topics, with the goal of Current Psychiatry GARY WATERS GARY Vol. 20, No. 2 9 Table 1 environment and health-vulnerability Considerations for LAI of the patient and the individuals living administration during COVID-19 with them. If the risk calculation does not point Should an LAI be continued? strongly towards a need for continuing Which LAI should be administered? the LAI, it may be prudent to temporar- When should the LAI be administered? ily transition the patient to the corre- LAIs during Where can the LAI be administered? sponding oral antipsychotic preparation. COVID-19 Who can administer the LAI? Table 2 (page 11) lists all LAIs available in the United States and their approximate What safety measures can be put in place to minimize risk to all parties? equivalent oral dosing. It is important to COVID-19: coronavirus disease 2019; LAI: long-acting note that such transitions are not without injectable antipsychotic clinical risk, to emphasize to the patient that the transition is intended as a tempo- rary measure, and to discuss a proposed timeline for re-initiating the LAI. Also, Clinical Point maintaining patients’ psychiatric stability emphasize to the patient and family that In some cases, it while protecting patients, health care work- this transition does not diminish the pre- ers, and the broader society from COVID-19 vious reasoning for needing an LAI, but may be prudent to infection. Table 1 summarizes the ques- is a temporary measure taken in light of temporarily transition tions regarding LAIs that clinicians need to weighing the risks and benefits during a the patient to the address during this crisis. While we focus pandemic. corresponding on outpatient care, inpatient teams should keep these considerations in mind if they oral antipsychotic are starting and discharging a patient on Which LAI should be preparation an LAI. More than ever, close collaboration administered? and communication between inpatient and If continuing the LAI is determined to be outpatient teams is critical. clinically necessary, consider switching the patient to a longer-acting preparation to maximize intervals between administra- Should an LAI be continued? tions and minimize the potential for infec- An important first step to approaching tion. From a public health perspective, the this challenge is to create a spreadsheet longest clinically prudent interval between for all patients receiving LAIs. Focusing injections may be the most important con- on a population-based approach is help- sideration, provided the patient can receive ful to be systematic and ensure that no a dose necessary to retain stability, and the patients fall through the cracks during LAI should be chosen accordingly. Deltoid this public health emergency.9 Once all injections may be able to be administered patients have been identified, the treat- with reduced contact, or on a “drive-up” ment team should review each patient to basis.10 Consider transitioning a patient determine if continuing to administer the who is receiving olanzapine pamoate antipsychotic as an LAI formulation is to an alternate LAI or oral formulation, essential, taking into account the patient’s because the 3-hour observation period current psychiatric status, historical medi- that is required after olanzapine pamoate cation adherence, potential severity and administration is particularly problematic. Discuss this article at dangerousness of decompensation if While it may not be ideal to make medica- www.facebook.com/ nonadherent, and structures to support tion changes during a pandemic, it is worth MDedgePsychiatry stability. For example, can a patient move carefully weighing the patient’s stability in with family who can monitor medica- and historical experience with other LAIs to tion adherence during the pandemic? Is determine if a safer/longer-spaced option it possible for the group home to assume is worth trying.11 medication administration? Additional We recommend only switching among Current Psychiatry 10 February 2021 consideration should be given to the living similar antipsychotics (ie, risperidone to Table 2 Long-acting injectable antipsychotics and equivalent oral dosing Medication Dosing schedule MDedge.com/psychiatry Abilify Aristada 882 mg 1,064 mg 882 mg 662 mg 441 mg q4wks q8wks q6wks q4wks q4wks Abilify Maintena 400 mg 300 mg 300 mg 300 mg 200 mg q4wks q4wks q4wks q4wks q4wks Abilify (PO) 20 mg 15 mg 15 mg 15 mg 10 mg Fluphenazine decanoate 25 mg 12.5 mg q3wks q2wks Fluphenazine (PO) 20 mg 10 mg Haldol decanoate 200 mg 100 mg q4wks q4wks Haldol (PO) 20 mg 10 mg Invega Trinza 819 mg 546 mg 410 mg 273 mg q12wks q12wks q12wks q12wks Invega Sustenna 234 mg 156 mg 117 mg 78 mg 39 mg Clinical Point q4wks q4wks q4wks q4wks q4wks If an LAI is necessary, Invega (PO) 12 mg 9 mg 6 mg 3 mg 1.5 mg consider switching Risperdal Consta 50 mg 37.5 mg 25 mg 12.5 mg q2wks q2wks q2wks q2wks to a longer-acting Perseris (subcutaneous) 120 mg 90 mg preparation q4wks q4wks to maximize Risperidone (PO) 4 mg 3 mg 2 mg 1 mg Zyprexa Relprevv 300 mg 405 mg 210 mg 300 mg 150 mg intervals between q2wks q4wks q2wks q4wks q2wks administrations Zyprexa (PO) 20 mg 15 mg 15 mg 10 mg 10 mg Source: Adapted from reference 1 PO: by mouth; q2wks: once every 2 weeks; q3wks: once every 3 weeks; q4wks: once every 4 weeks; q8wks: once every 8 weeks; q12wks: once every 12 weeks paliperidone), or between different prepara- with oral medications. For patients who tions of the same drug (ie, Abilify Maintena are in quarantine, it may be better to delay to Aristada), if possible, as these are the low- an injection until the patient ends their est risk transitions with regards to relapse. quarantine than to deliver the dose dur- Table 3 (page 12) provides examples. ing quarantine. Administering an injec- tion earlier also is usually safe; off-cycle visits may help minimize patient contact When should the LAI be (ie, if the patient happens to be coming administered? into the vicinity of the clinic, or requires The pharmacokinetics of LAIs allow for phlebotomy for therapeutic drug monitor- some flexibility in terms of when an LAI ing), and assist in planning for possible needs to be administered. The package resurgences. When appropriate, and after inserts of all second-generation LAIs considering the risk of worsening adverse include missed-dose guidelines. These effects, administering a higher dose than guidelines provide information on how the usual maintenance dose would pro- long one can wait before the next injec- vide a buffer if the next injection was to tion is due, and what additional measures be delayed. Therapeutic drug monitoring must be taken when beyond that date. can help to optimize dosing and avoid low Delaying an injection may be prudent, and plasma drug levels,
Load more

Recommended publications
  • Drug Use Evaluation: Antipsychotic Utilization in Schizophrenia Patients
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Drug Use Evaluation: Antipsychotic Utilization in Schizophrenia Patients Research Questions: 1. How many schizophrenia patients are prescribed recommended first-line second-generation treatments for schizophrenia? 2. How many schizophrenia patients switch to an injectable antipsychotic after stabilization on an oral antipsychotic? 3. How many schizophrenia patients are prescribed 2 or more concomitant antipsychotics? 4. Are claims for long-acting injectable antipsychotics primarily billed as pharmacy or physician administered claims? 5. Does adherence to antipsychotic therapy differ between patients with claims for different routes of administration (oral vs. long-acting injectable)? Conclusions: In total, 4663 schizophrenia patients met inclusion criteria, and approximately 14% of patients (n=685) were identified as treatment naïve without claims for antipsychotics in the year before their first antipsychotic prescription. Approximately 45% of patients identified as treatment naïve had a history of remote antipsychotic use, but it is unclear if antipsychotics were historically prescribed for schizophrenia. Oral second-generation antipsychotics which are recommended as first-line treatment in the MHCAG schizophrenia algorithm were prescribed as initial treatment in 37% of treatment naive patients and 28% of all schizophrenia patients. Recommended agents include risperidone, paliperidone, and aripiprazole. Utilization of parenteral antipsychotics was limited in patients with schizophrenia. Overall only 8% of patients switched from an oral to an injectable therapy within 6 months of their first claim. Approximately, 60% of all schizophrenia patients (n=2512) had claims for a single antipsychotic for at least 12 continuous weeks and may be eligible to transition to a long-acting injectable antipsychotic.
    [Show full text]
  • Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment for Schizophrenia in Adult Patients? Kyle J
    Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Student Dissertations, Theses and Papers Scholarship 2017 Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients? Kyle J. Knowles Philadelphia College of Osteopathic Medicine Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews Part of the Psychiatry Commons Recommended Citation Knowles, Kyle J., "Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients?" (2017). PCOM Physician Assistant Studies Student Scholarship. 381. https://digitalcommons.pcom.edu/pa_systematic_reviews/381 This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For more information, please contact [email protected]. Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients? Kyle J. Knowles, PA-S A SELECTIVE EVIDENCE BASED MEDICINE REVIEW In Partial Fulfillment of the Requirements For The Degree of Master of Science In Health Sciences- Physician Assistant Department of Physician Assistant Studies Philadelphia College of Osteopathic Medicine Philadelphia, Pennsylvania December 16, 2016 ABSTRACT OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is Aristada (aripiprazole lauroxil) a safe and effective treatment for schizophrenia in adult patients?” STUDY DESIGN: Review of three randomized controlled studies. All three trials were conducted between 2014 and 2015. DATA SOURCES: One randomized, controlled trial and two randomized, controlled, double- blind trials found via Cochrane Library and PubMed.
    [Show full text]
  • Second-Generation Long-Acting Injectable Antipsychotics: a PRACTICAL GUIDE Understanding Each of These Medications’ Unique Properties Can Optimize Patient Care
    Second-generation long-acting injectable antipsychotics: A PRACTICAL GUIDE Understanding each of these medications’ unique properties can optimize patient care Brittany L. Parmentier, PharmD, MPH, here are currently 7 FDA-approved second-generation long-acting BCPS, BCPP 1-7 Clinical Assistant Professor injectable antipsychotics (LAIAs). These LAIAs provide a Department of Pharmacy Practice Tunique dosage form that allows patients to receive an antipsy- The University of Texas at Tyler Fisch College of Pharmacy chotic without taking oral medications every day, or multiple times per Tyler, Texas day. This may be an appealing option for patients and clinicians, but Disclosure The author reports no financial relationships with any because there are several types of LAIAs available, it may be difficult to companies whose products are mentioned in this article, or with determine which LAIA characteristics are best for a given patient. manufacturers of competing products. Since the FDA approved the first second-generation LAIA, risperidone long-acting injectable (LAI),1 in 2003, 6 additional second-generation LAIAs have been approved: • aripiprazole LAI • aripiprazole lauroxil LAI • olanzapine pamoate LAI • paliperidone palmitate monthly injection • paliperidone palmitate 3-month LAI • risperidone LAI for subcutaneous (SQ) injection. When discussing medication options with patients, clinicians need to consider factors that are unique to each LAIA. In this article, I describe the similarities and differences among the second-generation LAIAs, and address common questions about these medications. A major potential benefit: Increased adherence One potential benefit of all LAIAs is increased medication adherence com- pared with oral antipsychotics. One meta-analysis of 21 randomized con- trolled trials (RCTs) that compared LAIAs with oral antipsychotics and Current Psychiatry GEORGE MATTEI/SCIENCE SOURCE GEORGE MATTEI/SCIENCE Vol.
    [Show full text]
  • Should Inverse Agonists Be Defined by Pharmacological Mechanism Or
    CNS Spectrums,(2019), 24 419 – 425. © Cambridge University Press 2018. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. doi:10.1017/S1092852918000986 ORIGINAL RESEARCH Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period Peter J. Weiden,1* Yangchun Du,2 Chih-Chin Liu,2 and Arielle D. Stanford3 1 Medical Affairs, Alkermes, Inc., Waltham, Massachusetts, USA 2 Clinical Development, Alkermes, Inc., Waltham, Massachusetts, USA 3 Clinical Science, Alkermes, Inc., Waltham, Massachusetts, USA Objective. Switching antipsychotic medications is common in patients with schizophrenia who are experiencing persistent symptoms or tolerability issues associated with their current drug regimen. This analysis assessed the safety of switching from an oral antipsychotic to the long-acting injectable antipsychotic aripiprazole lauroxil (AL). Methods. This was a post hoc analysis of outpatients with schizophrenia who were prescribed an oral antipsychotic and who enrolled in an international, open-label, long-term (52-week) safety study of AL. The analysis focused on the first 3 injections of AL 882 mg over 12 weeks, divided into the immediate 4-week crossover period between the first and second AL injections (initiation phase) and the subsequent 8 weeks (stabilization phase). Patients were grouped by preswitch oral antipsychotic medication, and safety and clinical symptoms were assessed. Results. In total, 190 patients had switched from one of the following oral antipsychotic medications: aripiprazole, conventional antipsychotics, risperidone/paliperidone, olanzapine, or quetiapine.
    [Show full text]
  • Aristada Initio (Aripiprazole Lauroxil), in Combination with Oral Aripiprazole for the Initiation of Aristada When Used for the Treatment of Schizophrenia in Adults
    Aristada Initio™ (aripiprazole lauroxil) – New drug approval • On July 2, 2018, Alkermes announced the FDA approval of Aristada Initio (aripiprazole lauroxil), in combination with oral aripiprazole for the initiation of Aristada when used for the treatment of schizophrenia in adults. — The approval of Aristada Initio provides physicians with an alternative regimen to initiate patients onto any dose of Aristada injection on day 1. — Previously, the first Aristada injection was recommended in conjunction with oral aripiprazole for 21 consecutive days. • Oral aripiprazole is generically available as tablets, disintegrating tablets, and solution. Aripiprazole is also available as Abilify Maintena®, a brand extended-release injectable suspension. — The oral formulations are approved for the treatment of schizophrenia and other indications as outlined in the individual drug labels. — Abilify Maintena is indicated for the treatment of schizophrenia in adults and as maintenance monotherapy treatment of bipolar I disorder in adults. • Aristada Initio leverages Alkermes’ proprietary NanoCrystal® technology, which provides an extended-release formulation using a smaller particle size compared to Aristada, thereby enabling faster dissolution and more rapid achievement of relevant drug levels. • The effectiveness of Aristada Initio, in combination with oral aripiprazole and for the initiation of Aristada injection, was established by adequate and well-controlled studies of oral aripiprazole and Aristada injection in adult patients with schizophrenia.
    [Show full text]
  • Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia
    brain sciences Review Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia Samskruthi Madireddy 1,* and Sahithi Madireddy 2 1 Independent Researcher, 1353 Tanaka Drive, San Jose, CA 95131, USA 2 Massachusetts Institute of Technology, 77 Massachusetts Ave, Cambridge, MA 02139, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-408-9214162 Received: 4 September 2020; Accepted: 15 October 2020; Published: 16 October 2020 Abstract: The biochemical integrity of the brain is paramount to the function of the central nervous system, and oxidative stress is a key contributor to cerebral biochemical impairment. Oxidative stress, which occurs when an imbalance arises between the production of reactive oxygen species (ROS) and the efficacy of the antioxidant defense mechanism, is believed to play a role in the pathophysiology of various brain disorders. One such disorder, schizophrenia, not only causes lifelong disability but also induces severe emotional distress; however, because of its onset in early adolescence or adulthood and its progressive development, consuming natural antioxidant products may help regulate the pathogenesis of schizophrenia. Therefore, elucidating the functions of ROS and dietary antioxidants in the pathogenesis of schizophrenia could help formulate improved therapeutic strategies for its prevention and treatment. This review focuses specifically on the roles of ROS and oxidative damage in the pathophysiology of schizophrenia, as well as the effects of nutrition, antipsychotic use, cognitive therapies, and quality of life on patients with schizophrenia. By improving our understanding of the effects of various nutrients on schizophrenia, it may become possible to develop nutritional strategies and supplements to treat the disorder, alleviate its symptoms, and facilitate long-term recovery.
    [Show full text]
  • ARISTADA INITIO® Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ___________________ CONTRAINDICATIONS ___________________ ARISTADA INITIO® safely and effectively. See full prescribing Known hypersensitivity to aripiprazole (4). information for ARISTADA INITIO®. _______________ WARNINGS AND PRECAUTIONS _______________ ARISTADA INITIO® (aripiprazole lauroxil) extended-release injectable • Cerebrovascular Adverse Reactions in Elderly Patients with Dementia- suspension, for intramuscular use Related Psychosis: Increased incidence of cerebrovascular adverse Initial U.S. Approval: 2015 reactions (e.g., stroke, transient ischemia attack, including fatalities) (5.2). • Potential for Dosing and Medication Errors: Substitution and dispensing WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS errors between ARISTADA INITIO and ARISTADA could occur. Do not WITH DEMENTIA-RELATED PSYCHOSIS substitute ARISTADA INITIO for ARISTADA (5.3). See full prescribing information for complete boxed warning. • Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring (5.4). • Elderly patients with dementia-related psychosis treated with • Tardive Dyskinesia: Discontinue if clinically appropriate (5.5). antipsychotic drugs are at an increased risk of death. (5.1) • Metabolic Changes: Monitor for hyperglycemia, dyslipidemia, and weight • ARISTADA INITIO is not approved for the treatment of patients with gain (5.6). dementia-related psychosis. (5.1) • Pathological Gambling and Other Compulsive Behaviors:
    [Show full text]
  • Aripiprazole Long-Acting Injection(Abilify Maintena
    Aripiprazole Long-acting Injection Aripiprazole Long-acting Injection (Abilify Maintena, ARISTADA) National Drug Monograph October 2013; Addendum March 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a comprehensive drug review for making formulary decisions. These documents will be updated when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. Executive Summary: Aripiprazole long-acting intramuscular injection (LAIM) is sixth antipsychotic and the fourth second generation antipsychotic to be marketed in a long-acting injection formulation. LAIM antipsychotics on the VA National Formulary: haloperidol and fluphenazine decanoate; risperidone; and paliperidone. Aripiprazole LAIM has FDA label indication for the treatment of schizophrenia. The initial and usual maintenance dose of aripiprazole is 400 mg once a month. The dose can be reduced to 300 mg or 200 mg monthly based on drug interactions or tolerability. Patients should have established tolerability to aripiprazole before receipt of the LAIM formulation. Oral aripiprazole, 10-30 mg/day, or another oral antipsychotic must be continued for 2-weeks after the initial dose, and then discontinued. Aripiprazole LAIM’s efficacy and safety are based on experience with the oral formulation as well as pharmacokinetic trials and a 52-week randomized, double-blind, placebo-controlled trial. The randomized trial was terminated early because the difference in time to relapse met a predetermined statistically significant threshold (p=0.001) favoring aripiprazole LAIM [HR 5.03, 95% CI 3.15-8.02].
    [Show full text]
  • Psychopharmacologic Updates
    Psychopharmacologic Updates Nimisha Gokaldas, MD Medical Director Multnomah County, Mental Health and Addiction Services Division This author has NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this presentation. History of Psychiatric drug development Mid-20th century showed saw the birth of modern psychopharmacology; the discovery of the first medicines that treated specific disorders. In 1949, lithium was tested on manic patients after John Cage noticed lithium urate salts sedating his guinea pigs. In 1950, chlorpromazine was initially used for its sedating properties, but the true benefit was really its ability to reduce hallucinations and delusions of patients with schizophrenia. In 1951, imipramine was initially developed for patients with schizophrenia, but was found to elevate mood, and became the prototype for antidepressant development. Fluoxetine was the first marketed SSRI in 1987 in the USA (Fluvoxamine was approved in 1983 in Switzerland and West Germany). History (con’t) The advent of drug discoveries in the 1950’s and 1960’s, motivated the research to understand the mechanism of actions that led to success of these medications Julius Axelrod won the Nobel Prize in 1970 for discovering neurotransmitter reuptake mechanisms. Arvid Carlsson won the Nobel Prize in 2000 for discovering that antipsychotic drugs work by blocking dopamine receptors. Antipsychotics “Golden era” of the 1950’s led to development of what we now refer to as the typical antipsychotics.
    [Show full text]
  • Should Inverse Agonists Be Defined by Pharmacological Mechanism Or
    CNS Spectrums,(2019), 24 354 – 370. © Cambridge University Press 2018. This is an Open Access article, distributed under the terms , of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work. doi:10.1017/S1092852918001098 REVIEW ARTICLE Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics Christoph U. Correll ,1,2 Jennifer Kern Sliwa ,3* Dean M. Najarian ,3 and Stephen R. Saklad4 1 Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, New York 2 Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York 3 Janssen Scientific Affairs LLC, Titusville, New Jersey 4 College of Pharmacy, Pharmacotherapy Division, University of Texas at Austin, San Antonio, Texas With more long-acting injectable (LAI) antipsychotics available for treating schizophrenia, each with variable durations of action (2 weeks to 3 months), it is important to have clear management strategies for patients developing breakthrough psychotic symptoms or experiencing symptomatic worsening on LAIs. However, no treatment guidelines or clinical practice pathways exist; health-care providers must rely on their own clinical judgment to manage these patients. This article provides practical recommendations—based on a framework of clinical, pharmacokinetic, and dosing considerations—to guide clinicians’ decisions regarding management of breakthrough psychotic symptoms.
    [Show full text]
  • Enrolled Copy SB 170 1 PHARMACY AND
    Enrolled Copy S.B. 170 1 PHARMACY AND PHARMACEUTICALS AMENDMENTS 2 2019 GENERAL SESSION 3 STATE OF UTAH 4 Chief Sponsor: Evan J. Vickers 5 House Sponsor: Brad M. Daw 6 7 LONG TITLE 8 General Description: 9 This bill amends provisions relating to the practice of pharmacy. 10 Highlighted Provisions: 11 This bill: 12 < amends the definition of "closed door pharmacy" and "practice as a licensed 13 pharmacy technician"; 14 < changes the requirements for certain supervising pharmacists; 15 < adds a drug to the list of long-acting injectable drug therapies that can be 16 administered by certain pharmacists; 17 < adds certain board certified urologists to the list of individuals who are qualified to 18 be a dispensing medical practitioner; and 19 < reschedules certain drugs that are approved by the United States Food and Drug 20 Administration and contain a component of cannabis. 21 Money Appropriated in this Bill: 22 None 23 Other Special Clauses: 24 None 25 Utah Code Sections Affected: 26 AMENDS: 27 58-17b-102, as last amended by Laws of Utah 2018, Chapter 295 28 58-17b-612, as last amended by Laws of Utah 2014, Chapter 72 29 58-17b-625, as enacted by Laws of Utah 2017, Chapter 384 S.B. 170 Enrolled Copy 30 58-17b-805, as enacted by Laws of Utah 2014, Chapter 72 31 58-37-4, as last amended by Laws of Utah 2018, Chapter 146 32 33 Be it enacted by the Legislature of the state of Utah: 34 Section 1. Section 58-17b-102 is amended to read: 35 58-17b-102.
    [Show full text]
  • CLINICAL REVIEW(S) Clinical Review David H
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209830Orig1s000 CLINICAL REVIEW(S) Clinical Review David H. Millis, MD NDA 209830 Aripiprazole lauroxil / Aristada Initio CLINICAL REVIEW Application Type NDA Application Number(s) 209830 Priority or Standard Standard Submit Date(s) August 31, 2017 Received Date(s) August 31, 2017 PDUFA Goal Date June 30, 2018 Division/Office Division of Psychiatry Products Reviewer Name(s) David H. Millis, MD Review Completion Date June 28, 2018 Established/Proper Name aripiprazole lauroxil (Proposed) Trade Name Aristada Initio Applicant Alkermes Dosage Form(s) intramuscular Applicant Proposed Dosing 675 mg single intramuscular injection Regimen(s) Applicant Proposed initiation of treatment of schizophrenia with Aristada Indication(s)/Population(s) Recommendation on Approve Regulatory Action Recommended initiation of treatment of schizophrenia with Aristada Indication(s)/Population(s) (if applicable) 1 Reference ID: 4284747 Clinical Review David H. Millis, MD NDA 209830 Aripiprazole lauroxil / Aristada Initio Table of Contents Glossary ........................................................................................................................................... 7 1. Executive Summary ................................................................................................................. 9 Product Introduction ........................................................................................................ 9 Conclusions on the Substantial Evidence of Effectiveness ...........................................
    [Show full text]